ASTH vs CLOV

For growth investors, Astrana Health, Inc.

(ASTH) is the stronger pick with 56. 4% revenue growth year-over-year, versus 40. 3% for Clover Health Investments, Corp. (CLOV). Astrana Health, Inc. (ASTH) offers the better valuation at 76. 6x trailing P/E (28. 5x forward), making it the more compelling value choice. Analysts rate Astrana Health, Inc. (ASTH) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Astrana Health, Inc.

is actually cheaper at 28. 5x.

Over the past 5 years, Astrana Health, Inc.

(ASTH) delivered a total return of +9. 4%, compared to -67. 4% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: ASTH returned +598. 0% versus CLOV's -73. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Astrana Health, Inc.

(ASTH) is the lower-risk stock at 1. 11β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 10% more volatile than ASTH relative to the S&P 500.

By revenue growth (latest reported year), Astrana Health, Inc.

(ASTH) is pulling ahead at 56. 4% versus 40. 3% for Clover Health Investments, Corp. (CLOV). On earnings-per-share growth, the picture is similar: Astrana Health, Inc. grew EPS -48. 9% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, ASTH leads at 40. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Astrana Health, Inc.

(ASTH) is the more profitable company, earning 0. 7% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 0. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ASTH leads at 2. 5% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Astrana Health, Inc.

(ASTH) trades at 28. 5x forward P/E versus 62. 6x for Clover Health Investments, Corp. — 34. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 24. 3% to $3. 33.

In this comparison, ASTH (0.

5% yield) pays a dividend. CLOV does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Astrana Health, Inc.

(ASTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11), +598. 0% 10Y return). Both have compounded well over 10 years (ASTH: +598. 0%, CLOV: -73. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.